#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Inclisiran receives reimbursement and enters clinical practice


Authors: Kristýna Čillíková
Authors‘ workplace: Česká společnost pro aterosklerózu
Published in: AtheroRev 2023; 8(2): 117-120
Category: Announcements


Sources

1. Ray KK, Kallend D, Leiter LA et al. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J 2022; 43(48): 5047–5057. <https://doi.org/10.1093/eurheartj/ehac615>.

2. Wright RS, Ray KK et al. Impact of Inclisiran on LDL-C Over 18 months in Patients With ASCVD or Risk-Equivalent - ORION-11. American College of Cardiology. Dostupné z WWW: <https://www.acc.org/latest-in-cardiology/ clinical-trials/2019/09/01/12/22/orion-11>.

Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adults

Article was published in

Athero Review

Issue 2

2023 Issue 2

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#